Defect‐engineered tungsten oxide nanowires as redox‐metabolic nanozymes for gut inflammation‐infection syndromes
Abstract
Abstract Inflammatory bowel disease (IBD) complicated by Salmonella infection features a coupled inflammation‐infection pathology driven by oxidative/nitrosative stress, barrier disruption, and microbiome imbalance. Here we report defect‐engineered tungsten oxide (WO 3 ) nanowires as a multifunctional nanozyme platform that integrates redox regulation, pathogen metabolic suppression, and mucosal repair. Defect programming generates abundant oxygen vacancies together with mixed‐valence W 4+ /W 5+ /W 6+ sites, which markedly enhances the catalytic scavenging of reactive oxygen and nitrogen species (reactive oxygen species/reactive nitrogen species) and enables effective control of intestinal redox stress. In parallel, WO 4 2− released from the nanowires competitively interfere with molybdate‐dependent nitrate reductase activity in Salmonella , thereby impairing nitrate respiration and ATP production to attenuate pathogen fitness. In vitro, the defect‐engineered WO 3 nanozymes protect intestinal epithelial cells from oxidative injury and inhibit Salmonella growth. In a DSS‐induced colitis model with Salmonella co‐infection, oral administration significantly alleviated inflammation, restored epithelial integrity, and rebalanced immune and microbial homeostasis. These results establish a defect‐guided redox‐metabolic therapeutic paradigm for addressing inflammation–infection interplay in the gut, and highlight defect‐engineered WO 3 nanowires as a promising chemical platform for complex intestinal disorders.